US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARIAD Pharmaceuticals

23.99

0.0000

Volume:- -

Turnover:- -

Market Cap:4.66B

PE:-133.28

High:23.99

Open:23.99

Low:23.99

Close:23.99

52wk High:23.99

52wk Low:23.99

Shares:194.20M

Float Shares:169.70M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1800

ROE:--

ROA:--

PB:-100.52

PE(LYR):- -

Loading ...

Overview Company News Filings

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

ARIA Cybersecurity adds features to expand AZT PROTECT

ARIA Cybersecurity, Acronis partner for AZT PROTECT integration

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Some AI Tokens on Binance Alpha See Significant Gains, ARIA Surges Over 88% in a Single Day

Press Release: GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARIA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIAD Pharmaceuticals","latestPrice":23.99,"timestamp":1764968400000,"preClose":23.99,"halted":0,"volume":0,"delay":0,"floatShares":169700000,"shares":194200862,"eps":-0.18,"marketStatus":"Not Yet Opened","change":0,"latestTime":"12-05 16:00:00 EST","open":23.99,"high":23.99,"low":23.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.18,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":23.99,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":169700000,"roa":"--","roe":"--","lyrEps":0,"shares":194200862,"dividePrice":0,"high":23.99,"amplitude":0,"preClose":23.99,"low":23.99,"week52Low":23.99,"pbRate":"-100.52","week52High":23.99,"institutionHeld":0.5771,"latestPrice":23.99,"eps":-0.18,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.18,"open":23.99,"prevYearClose":23.99,"prevWeekClose":23.99,"prevMonthClose":23.99,"prevQuarterClose":23.99,"fiveDayClose":23.99,"twentyDayClose":23.99,"sixtyDayClose":23.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-07","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-07-28","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1469678400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-10","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1462852800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-23","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1456203600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2015-11-03","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1446526800000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARIA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588302060","title":"Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588302060","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588302060?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803400,"startTime":"0","endTime":"0","summary":"Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started tre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199431/0/en/Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimer-s-Disease-at-the-Clinical-Trials-on-Alzheimer-s-Di.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","CAA","ARIA","MCI","AD"],"gpt_icon":0},{"id":"2588186061","title":"New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2588186061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588186061?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:40","pubTimestamp":1764711600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Dec.  02, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3198449/0/en/New-Data-Presented-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-lecanemab-irmb-on-Neurotoxic-A%CE%B2-Protofibrils-in-CSF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","MCI","BK4132","ARIA","AD","CAA"],"gpt_icon":0},{"id":"2588727630","title":"ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727630","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727630?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new plasma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196921/0/en/ProMIS-Neurosciences-Announces-New-Peer-Reviewed-Publication-Showing-Plasma-pTau-as-a-Predictive-Early-Endpoint-in-Alzheimer-s-trials-Supporting-its-Ongoing-Phase-1b-PRECISE-AD-tri.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","ARIA","PD","LU1169589451.USD","BK4143","BK4526","LU1169590202.USD","MSA","BK4023","LU0053671581.USD","BK4595","BK4132","LU0728928796.USD","LU1923622291.USD","BK4170","AD","BK4600","LU2211815571.USD","LU2125909916.SGD","LU1815336091.USD","LU2125909759.SGD","USA"],"gpt_icon":1},{"id":"2588223137","title":"ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223137","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223137?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, Dec.  01, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s dise","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196854/0/en/ProMIS-Neurosciences-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","USA","BK4600","LU0053671581.USD","LU0128526141.USD","BK4170","BK4218","LU1815336091.USD","BK4585","LU2125909759.SGD","BK4581","XLV","MSA","ARIA","LU0757428866.USD","LU1923622291.USD","LU0029874061.USD","LU2125909916.SGD","LU1169589451.USD","LU0728928796.USD","BK4137","PK","LU1169590202.USD","LABU","BK4588","LU2211815571.USD","BK4132","BK4181","HCSG","XBI","BK4143","BK4595","PD","BK4526","AD"],"gpt_icon":1},{"id":"2586478988","title":"Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478988","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478988?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194237/0/en/Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI-IQLIK-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG0V08.USD","MCI","AD","IE00BYQQ9H92.USD","BK4585","BK4132","IE00B5TLWC47.USD","BK4588","CAA","BK4104","FAST","BK4567","ARIA"],"gpt_icon":0},{"id":"2582764413","title":"ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582764413","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582764413?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186059/0/en/ProMIS-Neurosciences-Announces-Third-Quarter-2025-Financial-Results-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","PK","BK4023","BK4526","BK4181","LU1169590202.USD","BK4600","LU1815336091.USD","PD","LU1923622291.USD","MSA","BK4143","BK4595","BK4170","LU2211815571.USD","LU0757428866.USD","AD","LU0053671581.USD","LU1169589451.USD","LU2125909759.SGD","ARIA","LU2125909916.SGD","LU0728928796.USD","USA","BK4218"],"gpt_icon":1},{"id":"2580228110","title":"ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580228110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580228110?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:05","pubTimestamp":1762203900,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, Nov.  03, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179794/0/en/ProMIS-Neurosciences-to-Participate-in-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169589451.USD","PK","LU0728928796.USD","LU0053671581.USD","LU0757428866.USD","LU1169590202.USD","BK4585","LU0029874061.USD","BK4137","LU0128526141.USD","LU1923622291.USD","LU2125909916.SGD","LABU","BK4143","BK4132","BK4023","XLV","ARIA","AD","HCSG","BK4588","USA","BK4181","BK4170","LU1815336091.USD","BK4581","LU2125909759.SGD","XBI","BK4595","BK4218","MSA","BK4526","LU2211815571.USD","BK4600"],"gpt_icon":1},{"id":"2579117282","title":"INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579117282","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579117282?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:05","pubTimestamp":1761854700,"startTime":"0","endTime":"0","summary":"Company to Host Conference Call Today, October 30, at 4:30pm ETBOCA RATON, Fla., Oct.  30, 2025  (GLOBE NEWSWIRE) -- INmune Bio Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and im","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177900/0/en/INmune-Bio-Inc-Announces-Third-Quarter-2025-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139","ARIA"],"gpt_icon":0},{"id":"2579147618","title":"ARIA Cybersecurity adds features to expand AZT PROTECT","url":"https://stock-news.laohu8.com/highlight/detail?id=2579147618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579147618?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:15","pubTimestamp":1761830132,"startTime":"0","endTime":"0","summary":"ARIA Cybersecurity announced a new feature set that allows OEMs to integrate patented AZT PROTECT into their products to provide a level of protect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-adds-features-to-expand-azt-protect-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-adds-features-to-expand-azt-protect-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","NTSK","ARIA"],"gpt_icon":0},{"id":"2577304736","title":"ARIA Cybersecurity, Acronis partner for AZT PROTECT integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2577304736","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577304736?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:40","pubTimestamp":1761223235,"startTime":"0","endTime":"0","summary":"ARIA Cybersecurity and Acronis announced a new partnership to safeguard large-scale OT operations around the world by integrating ARIA’s patented A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-acronis-partner-for-azt-protect-integration-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-acronis-partner-for-azt-protect-integration-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTSK","BK4097","ARIA"],"gpt_icon":0},{"id":"2577361158","title":"ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2577361158","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577361158?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:30","pubTimestamp":1761132600,"startTime":"0","endTime":"0","summary":"Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct.  22,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3170990/0/en/ProMIS-Neurosciences-Strengthens-Board-with-Appointment-of-Slanix-Paul-Alex-Pharm-D-President-and-Portfolio-Manager-Public-Equity-of-Ally-Bridge-Group.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1169589451.USD","LU0053671581.USD","PD","MSA","BK4559","BK4218","ARIA","LU1169590202.USD","LU1791807156.HKD","EQR","BK4588","LU2125909916.SGD","LU0106831901.USD","LU2211815571.USD","PK","LU1815336091.USD","BK4023","ALLY","BK4166","BK4526","BK4595","BK4600","LU0728928796.USD","LU1668664300.SGD","BK4170","BK4143","BK4561","BK4132","LU1923622291.USD","BK4181","LU2125909759.SGD","AD","LU0757428866.USD","USA","BK4215"],"gpt_icon":1},{"id":"2575589231","title":"LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”","url":"https://stock-news.laohu8.com/highlight/detail?id=2575589231","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575589231?lang=en_us&edition=fundamental","pubTime":"2025-10-14 07:30","pubTimestamp":1760398200,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Oct.  13, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165850/0/en/LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIME-s-Best-Inventions-of-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIME","BK4132","CAA","AD","ARIA","MCI"],"gpt_icon":0},{"id":"2566761739","title":"Some AI Tokens on Binance Alpha See Significant Gains, ARIA Surges Over 88% in a Single Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2566761739","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566761739?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:36","pubTimestamp":1757676960,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 12th, according to market data, today some AI tokens on Binance Alpha have shown significant gains, including:ARIA surged over 88% in a single day, with a 24-hour trading volume of $7.5447 million;NAORIS saw a daily increase of 43.32%, with a 24-hour trading volume of $1.1504 million;GATA experienced a daily gain of 35.49%, with a 24-hour trading volume of $6.7845 million;VELVET recorded a daily increase of 33.93%, with a 24-hour trading volume of $0.895 million.BlockBeats reminds users that these related token prices are highly volatile, with relatively small trading volumes, so users should invest cautiously.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/312025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/312025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["ARIA"],"gpt_icon":0},{"id":"2566605487","title":"Press Release: GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2566605487","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566605487?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:00","pubTimestamp":1757505600,"startTime":"0","endTime":"0","summary":"--  The anticipated acquisition aligns with GE HealthCare's precision care. strategy with the goal of strengthening the company's portfolio of. offerings in neurological care and its quantitative analysis of brain. --  icometrix's icobrain platform -- a comprehensive set of solutions for. neurological disease analysis -- includes icobrain aria, the first AI. detecting known side effects of amyloid targeting therapies used to treat. GE HealthCare  today announced it has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer's disease to meet the growing demand for MRI in personalized treatment planning.\"Along with our commitment to pushing the barriers of neuroscience research with our innovative MRI technology, we're dedicated to strengthening our neurology portfolio and our MR im","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4555","LU2756315318.SGD","LU1366333091.USD","LU1988902786.USD","LU1093756325.SGD","LU1366192091.USD","LU2756315664.SGD","LU0267386448.USD","LU0689626769.HKD","GEHC","BK4585","LU0820562030.AUD","TM","LU0820561909.HKD","LU2168563687.JPY","LU2168564495.EUR","LU1551013342.USD","LU2168564222.USD","LU2543165471.USD","LU0640476718.USD","LU1064131342.USD","LU1261432733.SGD","LU1280957306.USD","ARIA","BK4187","LU2168564065.EUR","BK4604","03160","LU0354030511.USD","LU0157215616.USD","BK4206","BK4082","BK4543","BK4099","GE","LU0354030438.USD","LU0820561818.USD","BK4501","LU0149725797.USD","LU2264538146.SGD","LU1551013425.SGD","BK4588","LU0124676726.USD","BK4566","LU0868494617.USD","LU0943347566.SGD","LU0689472784.USD","LU2168564149.EUR"],"gpt_icon":0},{"id":"2564169360","title":"ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2564169360","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564169360?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:00","pubTimestamp":1756897200,"startTime":"0","endTime":"0","summary":"Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 12","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143435/0/en/ProMIS-Neurosciences-Receives-DSMB-Approval-to-Advance-to-Final-Dose-Escalation-Cohort-in-Phase-1b-Alzheimer-s-Trial-of-PMN310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909916.SGD","BK4143","BK4170","LU0728928796.USD","LU0053671581.USD","USA","PK","ARIA","BK4023","LU2125909759.SGD","PD","BK4600","LU1169589451.USD","BK4526","BK4595","LU1815336091.USD","MSA","LU1923622291.USD","CAN","AD","BK4181","LU1169590202.USD","BK4218","BK4132","LU0757428866.USD","LU2211815571.USD"],"gpt_icon":0},{"id":"2564334857","title":"Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2564334857","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564334857?lang=en_us&edition=fundamental","pubTime":"2025-09-03 07:30","pubTimestamp":1756855800,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3143241/0/en/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the-U-S-FDA-for-LEQEMBI-IQLIK-lecanemab-irmb-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzhei.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4132","ARIA","BK4588","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","BK4585","IE00BFXG0V08.USD","FAST","BK4567","AD","MCI","CAA"],"gpt_icon":0},{"id":"2563072015","title":"FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072015?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:00","pubTimestamp":1756501200,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HF","CDR","CSF","BK4110","BK4080","AAIC","MCI","BK4132","ARIA","AD","CAA"],"gpt_icon":0},{"id":"2559602868","title":"ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559602868","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559602868?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:00","pubTimestamp":1755082800,"startTime":"0","endTime":"0","summary":"U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Ov","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132444/0/en/ProMIS-Neurosciences-Announces-Second-Quarter-2025-Financial-Results-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4526","BK4595","LU1169590202.USD","BK4218","LU2125909916.SGD","BK4023","PD","CSF","USA","BK4600","LU1923622291.USD","LU0728928796.USD","LU1815336091.USD","BK4170","LU2211815571.USD","ARIA","AD","BK4143","MSA","LU2125909759.SGD","BK4181","LU1169589451.USD","LU0053671581.USD","LU0757428866.USD"],"gpt_icon":1},{"id":"2555056271","title":"ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2555056271","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555056271?lang=en_us&edition=fundamental","pubTime":"2025-07-29 20:00","pubTimestamp":1753790400,"startTime":"0","endTime":"0","summary":"Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123184/0/en/ProMIS-Neurosciences-to-Showcase-Protein-Misfolding-Drug-Discovery-Platform-PRECISE-AD-Trial-Design-at-the-2025-Alzheimer-s-Association-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0728928796.USD","PD","LU2211815571.USD","BK4595","BK4110","LU0757428866.USD","BK4218","LU2125909916.SGD","BK4181","BK4170","MSA","BK4526","USA","LU1169590202.USD","ARIA","LU1923622291.USD","PK","BK4023","LU2125909759.SGD","LU0053671581.USD","AAIC","LU1169589451.USD","BK4143","LU1815336091.USD","BK4600"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}